PT -期刊文章盟今敏OM AU -丹尼尔,Z AU -黑色,CM AU -杜波依斯,RM TI -间隙吸入锝99 m -二乙三胺五醋酸作为肺血管疾病的临床指标在系统性硬化症DP - 1999年1月01 TA -欧洲呼吸杂志》第六PG - 133 - 136 - 13的IP - 1 4099 - //www.qdcxjkg.com/content/13/1/133.short 4100 - //www.qdcxjkg.com/content/13/1/133.full所以欧元和J1999 1月01;13 AB -本研究评估的效用的间隙时间吸入二乙撑三胺pentaacetate(二乙三胺五醋酸)区分肺血管疾病和早期fibrosing牙槽炎(FA)在系统性硬化症患者(SSc)。这是推测,这个会保存在血管疾病患者与FA相比,尽管类似气体运移赤字和匹配的肺容积,因为保护肺泡上皮的完整性。所有患者SSc和被分为对照组(C;n = 9),肺血管组织(血管;n=14) or FA group (n=14) dependent on the appearance on a computed tomography (CT) scan and the transfer factor of the lung for carbon monoxide (T(L,CO)) (VAS and FA < or =70%, C > or =80%). All patients had a forced vital capacity (FVC) of >80%. The T(L,CO) (median) was similar in the VAS (57.5%) and FA (60%) groups. There was a significant difference in median DTPA clearance half-times between FA (21.25 min) and VAS (46.5 min) (p=0.014) and between FA and C (84.5 min) (p=0.0004). No difference was found between VAS and C (p=0.0778). Follow-up data from the VAS group showed no subsequent development of FA on the CT scan and no decrease in FVC (n=13, mean 42 months). These results suggest that clearance of diethylenetriamine pentaacetate is preserved in patients likely to have pulmonary vascular disease and may be useful in distinguishing fibrosing alveolitis from vascular disease in systemic sclerosis.